Authors: Qiang Fu YanPeng Li Yuan Gao SongHua Yang PeiQi Lu Min Jia LiRong Zhang
Publish Date: 2012/12/22
Volume: 69, Issue: 6, Pages: 1269-1274
Abstract
We recruited 363 unrelated hyperlipidemic patients with the CYP3A41/1 CYP3A51/1 and CYP3AP11/1 genotypes 189 of these were treated with atorvastatin and 174 were treated with simvastatin as a singleagent therapy 20 mg day−1 orally for 4 weeks The genotyping of SLCO1B1 c521T C pV174A OATPC5 was performed with allelespecific polymerase chain reaction ASPCR and PCR restriction fragment length polymorphism RFLP was performed to detect the carriers of SLCO1B1 c388A G pN130D OATPC1b Serum triglyceride TGs total cholesterol TC lowdensity lipoprotein cholesterol LDLC and highdensity lipoprotein cholesterol HDLC levels were determined before and after treatmentThe frequencies of the SLCO1B1 521T C and 388A G variant alleles in Chinese hyperlipidemic patients were found to be 162 and 721 respectively After treatment with 20 mg simvastatin or atorvastatin daily for 4 weeks TC TG and LDLC concentrations were lower than at baseline on average by 181 ± 37 258 ± 97 277 ± 54 in the simvastatintreated group and 175 ± 37 226 ± 86 275 ± 55 in the atorvastatintreated group respectively and the mean relative reduction in serum HDL cholesterol did not reach statistical significance −10 ± 109 05 ± 93 However no significant differences were observed in the lipidlowering effects of atorvastatin and simvastatin between subjects with different SLCO1B1 genotypesThe SLCO1B1 521T C and 388A G variants were found to be relatively common in Chinese patients with essential hyperlipidemia These frequencies were found to be similar to those observed in healthy Chinese and Japanese individuals but significantly different from Caucasians and blacks SLCO1B1 521T C and 388A G polymorphisms may not be associated with the lipidlowering effects of atorvastatin and simvastatin
Keywords: